Home » ALGETA REPORTS HRPC STUDY DATA
ALGETA REPORTS HRPC STUDY DATA
Algeta has announced that an analysis of the biomarker data from a Phase II trial of its lead product Alpharadin (radium-223) continues to demonstrate its potential as a treatment for bone metastases in hormone-refractory prostate cancer (HRPC) patients.
The company is conducting trial BC1-02 as part of its Phase II clinical program for Alpharadin, a novel radiopharmaceutical based on the alpha particle emitter radium-223, which naturally targets and attacks skeletal metastases. The double-blind placebo-controlled trial involves 64 patients with painful skeletal metastases as a consequence of HRPC and is in its follow-up phase at 11 centers in Norway, Sweden and the UK. The trial was fully enrolled in May 2005.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May